TY - JOUR
T1 - 5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors
AU - Ai, Teng
AU - Wilson, Daniel J.
AU - More, Swati S.
AU - Xie, Jiashu
AU - Chen, Liqiang
PY - 2016/4/28
Y1 - 2016/4/28
N2 - Derived from our previously reported human sirtuin 2 (SIRT2) inhibitors that were based on a 5-aminonaphthalen-1-yloxy nicotinamide core structure, 5-((3-amidobenzyl)oxy)nicotinamides offered excellent activity against SIRT2 and high isozyme selectivity over SIRT1 and SIRT3. Selected compounds also exhibited generally favorable in vitro absorption, distribution, metabolism, and excretion properties. Kinetic studies revealed that a representative SIRT2 inhibitor acted competitively against both NAD+ and the peptide substrate, an inhibitory modality that was supported by our computational study. More importantly, two selected compounds exhibited significant protection against α-synuclein aggregation-induced cytotoxicity in SH-SY5Y cells. Therefore, 5-((3-amidobenzyl)oxy)nicotinamides represent a new class of SIRT2 inhibitors that are attractive candidates for further lead optimization in our continued effort to explore selective inhibition of SIRT2 as a potential therapy for Parkinson's disease.
AB - Derived from our previously reported human sirtuin 2 (SIRT2) inhibitors that were based on a 5-aminonaphthalen-1-yloxy nicotinamide core structure, 5-((3-amidobenzyl)oxy)nicotinamides offered excellent activity against SIRT2 and high isozyme selectivity over SIRT1 and SIRT3. Selected compounds also exhibited generally favorable in vitro absorption, distribution, metabolism, and excretion properties. Kinetic studies revealed that a representative SIRT2 inhibitor acted competitively against both NAD+ and the peptide substrate, an inhibitory modality that was supported by our computational study. More importantly, two selected compounds exhibited significant protection against α-synuclein aggregation-induced cytotoxicity in SH-SY5Y cells. Therefore, 5-((3-amidobenzyl)oxy)nicotinamides represent a new class of SIRT2 inhibitors that are attractive candidates for further lead optimization in our continued effort to explore selective inhibition of SIRT2 as a potential therapy for Parkinson's disease.
UR - http://www.scopus.com/inward/record.url?scp=84966267363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966267363&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.5b01376
DO - 10.1021/acs.jmedchem.5b01376
M3 - Article
C2 - 26982234
AN - SCOPUS:84966267363
SN - 0022-2623
VL - 59
SP - 2928
EP - 2941
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 7
ER -